NCT05028582Phase 3Completed

Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)

Study sponsor: Arcutis Biotherapeutics, Inc. · ARQT

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2022-06-03Actual

Enrollment · participants432Actual

Source updated2025-07-17Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Scalp Psoriasis

Treatments or interventions studied

Roflumilast Foam 0.3%DrugAlso known as ARQ-154 0.3%
Vehicle FoamDrug

Primary outcomes · main study measures

Read the study measures

measure: Achievement of Scalp Investigator Global Assessment (S-IGA) "Success" at Week 8; description: The percentage of participants with S-IGA success at Week 8 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline at Week 8. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.; timeFrame: Week 8; measure: Achievement of Body Investigator Global Assessment (B-IGA) Success at Week 8; description: The percentage of participants with B-IGA success at Week 8 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline at Week 8. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2),Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.; timeFrame: Week 8

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history